PMID: 20653195Jul 27, 2010Paper

Two cases of therapy-related myelodysplastic syndrome after concurrent oral cancer chemoradiotherapy

Nihon Jibiinkoka Gakkai kaiho
Katsuyuki DoiTakashi Kinoshita

Abstract

Therapy-related myelodysplastic syndrome (t-MDS) and therapy-related leukemia (TRL) are reported increasingly often, and we report two cases of T-MDS after concurrent chemoradiotherapy (CCRT) with oral cancer. Patients underwent CCRT with cisplatin (CDDP) or carboplatin (CBDCA). The interval between primary CCRT and t-MDS was 11 months in 1 case and 14 years in the other. Chromosomal analysis indicated abnormal karyotypes. Platinum has a relatively lower t-MDS risk than alkylating agents or topoisomerase II inhibitors, but our experience supports concurrent use of radiotherapy with platinum affects the risk of t-MDS. If pancytopenia is detected after CCRT, bone marrow and cytogenetic examinations should be conducted to rule out T-MDS.

References

Feb 4, 1999·The New England Journal of Medicine·L B TravisM Stovall
Jul 31, 2003·Drugs·Uzair B Chaudhary, Jason R Haldas
Jan 16, 2007·Breast Cancer Research and Treatment·Regan A HowardLois B Travis
Sep 5, 2007·Haematologica·Giuseppe LeoneMaria Teresa Voso

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.